Trial Profile
The efficacy and tolerability of discontinuing treatment with natalizumab in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2014
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 24 Apr 2014 New trial record